GSK secures rights to Syndivia’s ADC asset for prostate cancer
GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal up to £268 million.
GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal up to £268 million.
Snapback Activation Not Economic Game-Changer A new study by the Iranian Parliament’s research arm has assessed the legal, political and e…
ASX Winners and Losers of Today The table ranks the 20 biggest percentage winners and losers among stocks in the ASX300 at the end of each…
Iran Cooperation with IAEA The basis for Iran's cooperation with the International Atomic Energy Agency (IAEA) is rooted in a piece of leg…
Cisco and G42 Deepen US-UAE Technology Partnership Cisco and G42 are expanding their collaboration to advance secure AI infrastructure in …
Herefordshire Couple Denied Solar Panels on Historic Farmhouse A government planning inspector has rejected a Herefordshire couple's appli…
Novartis to Acquire Avidity Biosciences Novartis will buy Avidity Biosciences for US$12 billion, gaining its RNA-based therapeutic platfor…
Making Children with Speech Disorders Comfortable on Halloween For children with speech or language disorders, saying "trick or treat" on …
Nordic Capital Acquires BMLL to Boost Financial Data Transparency IBS Intelligence, a leading financial technology research and advisory f…
Nearly 2,000 People Attend Community Event Nearly 2,000 people attended Godmanchester's Apple Day at the Community Plant Nursery on Octobe…
Social Security in 2026: Experts Weigh in on Plans Social Security has had a significant impact, lifting 22 million Americans out of pover…